Dynavax Technologies has been granted a patent for alkyl chain modified 1H-imidazoquinoline compounds that act as Toll-like receptor-7 and -8 agonists. The patent includes methods for creating pharmaceutical compositions and their use in stimulating immune responses in mammals for disease treatment. GlobalData’s report on Dynavax Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dynavax Technologies, Personalized cancer vaccines was a key innovation area identified from patents. Dynavax Technologies's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Immune response stimulation using modified imidazoquinoline compounds
The granted patent US11981670B2 outlines methods for stimulating immune responses in mammalian subjects through the administration of specific pharmaceutical compositions. The core of the invention involves a compound designated as formula (J), or its salts, combined with a pharmaceutically acceptable excipient. The claims detail various configurations of the compound, particularly focusing on the substituents R0 and RA, which can include cycloalkyl groups and specific carbon chain lengths. The methods aim to induce both general immune responses and antigen-specific antibody or T cell responses, with particular emphasis on the structural variations of the compound that may enhance efficacy.
Further claims specify the structural parameters of the compound, including variations in the carbon chain length (m and z) and the nature of the cycloalkyl groups (RA). The patent also mentions specific compounds (e.g., Compound No. 63-33, 63-35, 63-36, and 63-38 to 63-49) that can be utilized within the pharmaceutical compositions. Additionally, the administration route is specified as intramuscular, which may be relevant for optimizing the immune response. Overall, the patent presents a detailed framework for developing immune-stimulating therapies based on the specified compounds and their structural characteristics.
To know more about GlobalData’s detailed insights on Dynavax Technologies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
